In Southampton, soccer moms drop their kids off at school after taking their thrice-weekly microdose of psilocybin mushrooms, then meet for oat milk lattes. In Sun Valley, private retreats dedicated to tripping on MDMA or the Amazonian elixir ayahuasca are becoming almost as common as backyard barbecues. (Just don’t bring the kids.) In Silicon Valley, tech entrepreneurs and financiers turned psychonauts believe that taking small doses of LSD, in either liquid or tab form, helps with creativity and productivity in the workforce. Even rightwing internet investor Peter Thiel has put a formidable stake in Compass Pathways, a publicly traded psychedelic medicine company.
But now there’s a weirder, wilder new drug appearing on the menu for moneyed types in search of mind expansion: the Toad, otherwise known as 5-MeO-DMT (or, if you really want to know its correct name, 5-methoxy-N, N-dimethyltryptamine), or DMT, or Bufo. In his landmark 2018 memoir, How to Change Your Mind, Michael Pollan referred to it as the Everest of psychedelics.
Hellbound and Down 